PHASTAR is a global biometrics CRO offering statistical consulting, clinical trial reporting, data management and data science services by providing expert consultants and managing and delivering in-house projects, FSP-style arrangements and preferred partnerships.
Our number one priority is ensuring on time, quality work: every project undertaken is supervised on methodology and utilizes internal processes designed to guarantee optimal quality, inspired by 3,000 years accumulated technical experience across the company.
PHASTAR is headquartered in London (UK) and North Carolina (US) and has 11 offices across four continents.
Services
Welcome to PHASTAR
PHASTAR is a global biometrics CRO offering statistical consulting, clinical trial reporting, data management and data science services by providing expert consultants and managing and delivering in-house projects, FSP-style arrangements and preferred partnerships.
Our number one priority is ensuring on time, quality work: every project undertaken is supervised on methodology and utilizes internal processes designed to guarantee optimal quality, inspired by 3,000 years accumulated technical experience across the company.
PHASTAR is headquartered in London (UK) and North Carolina (US) and has 12 offices across four continents.
Services
Interested? Click on the button to see our Case Studies
We are experts in study design, statistical analysis, data science, data capture and reporting for clinical trials
Recent blogs
-
View from the summit: The Best Laid Plans...Navigating Uncertainty During COVID-19
Day 2 of PHASTAR’s Life Science Summit began with an insightful and engaging plenary panel discussion with Dr. Janet Wittes,… Read More -
View from the Summit: Prof Thomas Jaki and the challenges of designing clinical trials during a pandemic
PHASTAR was delighted to welcome Prof. Thomas Jaki to the opening plenary session of PHASTAR’s Life Science Summit. Conducting clinical… Read More -
Epidemiological models for COVID-19: Why so many models and why all the fuss?
Years ago, I spent several months painfully developing a mathematical prediction model to evaluate decreases in cervical cancer prevalence assuming… Read More
- 1